LDN Social Media
Get connected with us on social networks
Breakthrough book spotlights the life-changing potential of low dose naltrexone (LDN) for chronic pain and complex conditions
The Phoenix Newspaper | Health and Wellbeing
8th June 2025
With millions suffering silently from chronic pain and complex conditions, The LDN Book 4: Case Studies in Chronic Pain (LDN Research Trust) is offering timely and life-changing insights into one of medicine's best-kept secrets — low dose naltrexone (LDN).
Publishing on June 6, 2025, and launching at the LDN 2025 Conference, this fourth instalment in the internationally renowned LDN Book series focuses on real-life case studies where patients have achieved remarkable improvements — and in some cases, complete transformations — through the use of LDN. From autoimmune diseases and hormonal imbalances to chronic pain syndromes like fibromyalgia, Ehlers-Danlos Syndrome, and inflammatory conditions, this new collection of case studies highlights LDN's growing potential as a non-toxic, low-cost, and accessible therapy.
Educator Kim Fields, who lives with chronic neurological pain, gave the book 5 stars on NetGalley: "Low-dose naltrexone is one of the best-kept secrets in the medical world.
“This book aims to shed light on how life-changing LDN can be for myriad conditions. My hope is that books like this will prompt more scientific research for LDN."
Meanwhile, medical professionals are taking note. NetGalley Reviewer Amethyst Maxey shared: "It was very educational and will be a great tool to add in my practice."
With Pain Awareness Month coming up in September, alongside Invisible Disabilities Week and World Mental Health Day (10 October), The LDN Book 4 arrives at a time when there is growing demand for alternative and integrative options for patients who have been left behind by mainstream medicine. Editor Linda Elsegood, founder of the LDN Research Trust, who lives in Norfolk, says: "This book is for patients, carers, and practitioners. The stories within it are real.
“They show what is possible with LDN — and why we urgently need more research, access, and education around this treatment."